{"id":21177,"date":"2022-02-25T14:22:31","date_gmt":"2022-02-25T13:22:31","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=21177"},"modified":"2022-02-25T14:22:35","modified_gmt":"2022-02-25T13:22:35","slug":"bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/","title":{"rendered":"BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics"},"content":{"rendered":"\n<p>Antibacterial drug discovery and development during the 20th century yielded one of the greatest armaments available to physicians, with more than 90% of all antibacterial drugs discovered during this period. Since the introduction of numerous antibiotic classes during the 1940s, deaths from bacterial infections have been reduced significantly. However, this next century is already presenting challenges that may render these older antibiotics obsolete. <\/p>\n\n\n\n<p>The COVID pandemic, which exposed multiple preparedness shortcomings, has elevated attention to the increasing threat of drug-resistant strains of bacteria. More than 1.2 million people worldwide are dying each year from antibiotic resistant infections and it is estimated this number will grow to 10 million per year by 2050. In the U.S. alone, more than 2.8 million antibiotic-resistant infections occur each year, with more than 35,000 people dying as a result.<\/p>\n\n\n\n<p>The CDC, EMEA, WHO, IDSA, Pew, and other groups have issued warnings to public policymakers for more than a decade about the reduced effectiveness of last century\u2019s antibiotic arsenal (see Appendix A1 for the most recent pathogen threat list from CDC and WHO).<\/p>\n\n\n\n<p>This report investigates recent investment into antibacterial innovation and the current clinical pipeline that will help bridge the gaps in the antibacterial armamentarium. In our previously published research, drug development investment for many common chronic diseases was found to be declining and low relative to total healthcare burden on society. <\/p>\n\n\n\n<p>In that survey of under-funded disease areas, antibiotic investment was also found to be low and not trending upward with the rest of the industry. Unfortunately, over the same time period the total number of infections has risen along with more reports of antibiotic resistance. The lack of investor interest can be seen by contrasting venture investment into antibiotics vs. cancer over the last decade.<\/p>\n\n\n\n<p>Oncology companies raised close to $7 billion in 2020 (up 900% from 2011), whereas antibiotic companies raised just $0.16 billion (less than what they raised 10 years prior). This prompted the ongoing investigation to expand our analysis beyond privately funded companies. Specifically, we investigate funding industry-wide and determine to what extent this weakness in funding has impacted innovative antibacterial drug candidates.<\/p>\n\n\n\n<p>Dowload report <a href=\"https:\/\/www.bio.org\/sites\/default\/files\/2022-02\/The-State-of-Innovation-in-Antibacterial-Therapeutics.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a>.<\/p>\n\n\n\n<p>About BIO<br>The Biotechnology Innovation Organization (BIO) is the world\u2019s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.<br>BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. BIO also produces the BIO International Convention, the world\u2019s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.<\/p>\n\n\n\n<p>Access BIO Industry Analysis reports <a href=\"http:\/\/www.bio.org\/iareports\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a>.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antibacterial drug discovery and development during the 20th century yielded one of the greatest armaments available to physicians, with more than 90% of all antibacterial drugs discovered during this period. Since the introduction of numerous antibiotic classes during the 1940s, deaths from bacterial infections have been reduced significantly. However, this next century is already presenting [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":21193,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-25T13:22:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-25T13:22:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Medical-research.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"783\" \/>\n\t<meta property=\"og:image:height\" content=\"429\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics\",\"datePublished\":\"2022-02-25T13:22:31+00:00\",\"dateModified\":\"2022-02-25T13:22:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/\"},\"wordCount\":442,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Medical-research.jpg\",\"articleSection\":[\"Bilans, rapports et recommandations\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/\",\"name\":\"BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Medical-research.jpg\",\"datePublished\":\"2022-02-25T13:22:31+00:00\",\"dateModified\":\"2022-02-25T13:22:35+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Medical-research.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Medical-research.jpg\",\"width\":783,\"height\":429,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Reviews, reports and recommendations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/","og_locale":"en_GB","og_type":"article","og_title":"BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2022-02-25T13:22:31+00:00","article_modified_time":"2022-02-25T13:22:35+00:00","og_image":[{"width":783,"height":429,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Medical-research.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics","datePublished":"2022-02-25T13:22:31+00:00","dateModified":"2022-02-25T13:22:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/"},"wordCount":442,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Medical-research.jpg","articleSection":["Bilans, rapports et recommandations"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/","name":"BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Medical-research.jpg","datePublished":"2022-02-25T13:22:31+00:00","dateModified":"2022-02-25T13:22:35+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Medical-research.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Medical-research.jpg","width":783,"height":429,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/bio-industry-analysis-reports-the-state-of-innovation-in-antibacterial-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"Reviews, reports and recommendations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/"},{"@type":"ListItem","position":4,"name":"BIO Industry Analysis reports: the State of Innovation in Antibacterial Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-16 17:08:49","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/21177"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=21177"}],"version-history":[{"count":18,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/21177\/revisions"}],"predecessor-version":[{"id":21217,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/21177\/revisions\/21217"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/21193"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=21177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=21177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=21177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}